The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz

被引:107
作者
Clarke, SM
Mulcahy, FM
Tjia, J
Reynolds, HE
Gibbons, SE
Barry, MG
Back, DJ
机构
[1] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GE, Merseyside, England
[2] St James Hosp, Dept Genitourinary Med, Dublin 8, Ireland
[3] St James Hosp, Dept Pharmacoecon, Dublin 8, Ireland
关键词
efavirenz; HIV; methadone;
D O I
10.1046/j.1365-2125.2001.00342.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims Methadone is predominantly metabolized by cytochrome P450 3A4 and the non nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz is a recognized inducer of this enzyme. We evaluated the pharmacokinetics of methadone in the presence and absence of efavirenz when administered to HIV infected patients with a history of injection drug use (IDU). Methods Eleven patients on stable methadone maintenance therapy, due to commence antiretroviral therapy (ART), participated in this study. Steady state methadone kinetic profiles were obtained on two occasions 0, 1, 2, 3, 4, 5, 6, 7, 8 and 24 h post dosing. Following centrifugation, separated plasma was heated at 58 degreesC for 30 min to inactivate HIV and stored at -80 degreesC until methadone analysis by high performance liquid chromatography. Results When combined with efavirenz there was a marked decrease in the maximum plasma concentration (C-max) of methadone from 689 (range 212-1568) to 358 (range 205-706) ng ml(-1), P=0.007:95% confidence interval (CI) 112-549. The mean area under the methadone concentration curve 0-24 h (AUC(0,24 h)) was also significantly reduced from 12341 (range 3683-34147) to 5309 (range 2430-10349) ng ml(-1) h in the presence of efavirenz, P = 0.012 : 95% CI 1921-12143. Nine patients described symptoms of methadone withdrawal and received a dose increase. Although methadone AUC(0,24 h) was reduced by over 50% following efavirenz the mean increase in methadone dose required was 22% (range 15-30 mg). Conclusion The inclusion of the NNRTI efavirenz in once daily ART for HIV patients with a history of IDU receiving methadone maintenance: results in a significant reduction in methadone plasma concentrations mediated by enzyme induction. It is important to distinguish efavirenz neurological effects which were observed between days 1-5 of therapy from symptoms of methadone withdrawal which occurred from day 8 onwards. The dose of methadone was adjusted by increments of 10 mg to counteract the efavirenz inducing effect.
引用
收藏
页码:213 / 217
页数:5
相关论文
共 25 条
  • [1] Efavirenz
    Adkins, JC
    Noble, S
    [J]. DRUGS, 1998, 56 (06) : 1055 - 1064
  • [2] Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone
    Altice, FL
    Friedland, GH
    Cooney, EL
    [J]. AIDS, 1999, 13 (08) : 957 - 962
  • [3] RIFAMPIN DRUG-INTERACTIONS
    BACIEWICZ, AM
    SELF, TH
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1984, 144 (08) : 1667 - 1671
  • [4] ENZYME-INDUCTION AND INHIBITION
    BARRY, M
    FEELY, J
    [J]. PHARMACOLOGY & THERAPEUTICS, 1990, 48 (01) : 71 - 94
  • [5] Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection
    Barry, M
    Mulcahy, F
    Merry, C
    Gibbons, S
    Back, D
    [J]. CLINICAL PHARMACOKINETICS, 1999, 36 (04) : 289 - 304
  • [6] Antiretroviral therapy for HIV infection in 1998 - Updated recommendations of the International AIDS Society USA panel
    Carpenter, CCJ
    Fischl, MA
    Hammer, SM
    Hirsch, MS
    Jacobsen, DM
    Katzenstein, DA
    Montaner, JSG
    Richman, DD
    Saag, MS
    Schooley, RT
    Thompson, MA
    Vella, S
    Yeni, PG
    Volberding, PA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (01): : 78 - 86
  • [7] Self-reported antiretroviral therapy in injection drug users
    Celentano, DD
    Vlahov, D
    Cohn, S
    Shadle, VM
    Obasanjo, O
    Moore, RD
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (06): : 544 - 546
  • [8] The effect of fluconazole on the clinical pharmacokinetics of methadone
    Cobb, MN
    Desai, J
    Brown, LS
    Zannikos, PN
    Rainey, PM
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (06) : 655 - 662
  • [9] METHADONE TOXICITY CAUSING DEATH IN 10 SUBJECTS STARTING ON A METHADONE-MAINTENANCE PROGRAM
    DRUMMER, OH
    OPESKIN, K
    SYRJANEN, M
    CORDNER, SM
    [J]. AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY, 1992, 13 (04) : 346 - 350
  • [10] FOGELMAN I, 1994, J ACQ IMMUN DEF SYND, V7, P1057